Group 1 - The core viewpoint of the article is that *ST Shuangcheng (002693.SZ) has confirmed that several of its products are included in the medical insurance catalog [1] - The products that are included in the medical insurance catalog are: Thymosin injection, Somatostatin injection, Famotidine injection, Clindamycin hydrochloride injection, Chuanxiong phosphate injection, and Octreotide acetate injection [1] - The company has not submitted an application for its product, Paclitaxel injection (albumin-bound), in the domestic market [1]

Group 1 - The company responded to an investor inquiry regarding the export volume of paclitaxel in the fourth quarter, indicating that financial data will be disclosed in periodic reports as per regulations [2] - The main source of revenue for the company is from pharmaceutical sales, with key products including injectable thymosin alpha 1, injectable paclitaxel (albumin-bound), injectable somatostatin, injectable bivalirudin, and injectable clindamycin hydrochloride [2]

Group 1 - The company *ST Shuangcheng (002693.SZ)* confirmed that several of its products have passed the consistency evaluation for generic drugs [2] - The products that have achieved this include Thymosin injection, Somatostatin injection, Octreotide injection, and Bortezomib injection [2]